Cargando…
Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
BACKGROUND: Population‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS i...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402846/ https://www.ncbi.nlm.nih.gov/pubmed/32558356 http://dx.doi.org/10.1002/cam4.3237 |